Joint Letter of Support for Swift Action on the MEDS Act
Dear Chairman Alexander and Ranking Member Murray,
As the United States takes steps in response to the outbreak of COVID-19, concerns with the integrity of the drug supply chain and the potential impact on downstream drug shortages have surfaced. While no drug shortages have been reported thus far in direct correlation with COVID-19, past situations such as H1N1, Ebola, and Hurricane Maria have highlighted vulnerabilities in the drug supply chain that require congressional action to ensure a stable supply of critical medications is available for patient care. Furthermore, the World Health Organization (WHO) and the Food and Drug Administration (FDA) have stated the COVID-19 outbreak will likely impact the medical product supply chain, including potential disruptions to supply or shortages of critical medical products in the United States.
Therefore, the undersigned organizations are writing in support of S.2723 – The Mitigating Emergency Drug Shortages (MEDS) Act which is a holistic and sustainable approach to eliminating drugs shortages and addressing vulnerabilities in the drug supply chain. We urge the Senate Committee on Health, Education, Labor, and Pensions (HELP) to advance this critical piece of legislation expeditiously.
Click here to read the full letter.
Comments of the Healthcare Supply Chain Association to FDA on Identifying the Root Causes of Drug Shortages and Finding Enduring Solutions
On behalf of the Healthcare Supply Chain Association (HSCA), we appreciate the...
Washington, DC (January, 2019) – The Healthcare Supply Chain Association (HSCA)...